Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ:APM)

0.8799 +0.0438 (+5.24%)
Streaming Delayed Price Updated: 10:18 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
From Aptorum Group Ltd
Via GlobeNewswire
Aptorum Group Ltd. (NASDAQ: APM) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Aptorum Group Ltd. (NASDAQ: APM) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR’s APOE Genotyping Test
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group Limited Regains Compliance with NASDAQ’s Minimum Bid Price Requirement
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
From Aptorum Group Ltd
Via GlobeNewswire
News headline image
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group Limited
Via Business Wire
Aptorum Group Ltd. (NASDAQ: APM) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group
Via Business Wire
News headline image
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
From Aptorum Group Limited
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.